Homocysteine as a peripheral biomarker in bipolar disorder: A meta-analysis

European Psychiatry

Volumn 43, Issue , 2017, Pages 81-91

  Salagre, E ^a,b   Vizuete, A F ^c   Leite, M ^c   Brownstein, D J ^d   McGuinness, A ^a   Jacka, F ^a   Dodd, S ^a,e   Stubbs, B ^f,g,h,i   Kohler C A ^j   Vieta, E ^b   Carvalho, A F ⁱ   Berk, M ^a,e   Fernandes, B S ^a,c  

^a BARWON HEALTH   (Australia)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF PADOVA   (Italy)

^h Institute of Clinical Research and Education in Medicine (IREM)   (Italy)

ⁱ SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^j FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

more..

Author keywords

Biomarker; Bipolar disorder; Homocysteine; Meta analysis; Precision psychiatry; Systematic review

Indexed keywords

HOMOCYSTEINE; BIOLOGICAL MARKER;

AMINO ACID BLOOD LEVEL; BIPOLAR DISORDER; CROSS-SECTIONAL STUDY; HUMAN; MANIA; META ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; BLOOD; CYCLOTHYMIA;

BIOMARKERS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; CYCLOTHYMIC DISORDER; HOMOCYSTEINE; HUMANS;

EID: 85016493638     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2017.02.482     Document Type: Short Survey

References (148)

1. [1] Alawieh, A., Zaraket, F.A., Li, J.L., Mondello, S., Nokkari, A., Razafsha, M., et al. Systems biology, bioinformatics, and biomarkers in neuropsychiatry. Front Neurosci, 6, 2012, 187.
2. [2] Domenici, E., Wille, D.R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One, 5, 2010, e9166.
3. [3] Frey, B.N., Andreazza, A.C., Houenou, J., Jamain, S., Goldstein, B.I., Frye, M.A., et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry 47 (2013), 321–332.
4. [4] Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011, The Cochrane Collaboration.
5. [5] Fernandes, B.S., Gama, C.S., Cereser, K.M., Yatham, L.N., Fries, G.R., Colpo, G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 45 (2011), 995–1004.
6. [6] Fernandes, B.S., Berk, M., Turck, C.W., Steiner, J., Goncalves, C.A., Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 19 (2014), 750–751.
7. [7] Fernandes, B.S., Molendijk, M.L., Kohler, C.A., Soares, J.C., Leite, C.M., Machado-Vieira, R., et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med, 13, 2015, 289.
8. [8] Fernandes, B.S., Steiner, J., Berk, M., Molendijk, M.L., Gonzalez-Pinto, A., Turck, C.W., et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry 20 (2015), 1108–1119.
9. [9] Molendijk, M.L., Spinhoven, P., Polak, M., Bus, B.A., Penninx, B.W., Elzinga, B.M., et al. concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 19 (2014), 791–800.
10. [10] Fernandes, B.S., Steiner, J., Bernstein, H.G., Dodd, S., Pasco, J.A., Dean, O.M., et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 21 (2016), 554–564.
11. [11] Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71 (2009), 171–186.
12. [12] Fernandes, B.S., Steiner, J., Molendijk, M.L., Dodd, S., Nardin, P., Goncalves, C.A., et al. C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 3:12 (2016), 1147–1156.
13. [13] Ghanizadeh, A., Singh, A.B., Berk, M., Torabi-Nami, M., Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. Expert Opin Ther Targets 19 (2015), 927–939.
14. [14] Cosar, A., Ipcioglu, O.M., Ozcan, O., Gultepe, M., Folate and homocysteine metabolisms and their roles in the biochemical basis of neuropsychiatry. Turk J Med Sci 44 (2014), 1–9.
15. [15] Yadav, U., Kumar, P., Gupta, S., Rai, V., Role of MTHFR C677T gene polymorphism in the susceptibility of schizophrenia: an updated meta-analysis. Asian J Psychiatr 20 (2016), 41–51.
16. [16] Numata, S., Kinoshita, M., Tajima, A., Nishi, A., Imoto, I., Ohmori, T., Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis. BMC Med Genet, 16, 2015, 54.
17. [17] Muntjewerff, J.W., Kahn, R.S., Blom, H.J., den Heijer, M., Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11 (2006), 143–149.
18. [18] Assies, J., Mocking, R.J., Lok, A., Ruhe, H.G., Pouwer, F., Schene, A.H., Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand 130 (2014), 163–180.
19. [19] Moustafa, A.A., Hewedi, D.H., Eissa, A.M., Frydecka, D., Misiak, B., Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Front Behav Neurosci, 8, 2014, 343.
20. [20] Baek, J.H., Bernstein, E.E., Nierenberg, A.A., One-carbon metabolism and bipolar disorder. Z J Psychiatry 47 (2013), 1013–1018.
21. [21] Hooshmand, B., Mangialasche, F., Kalpouzos, G., Solomon, A., Kareholt, I., Smith, A.D., et al. Association of vitamin B12, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal population-based study. JAMA Psychiatry 73 (2016), 606–613.
22. [22] Kolling, J., Scherer, E.B., Siebert, C., Longoni, A., Loureiro, S., Weis, S., et al. Severe hyperhomocysteinemia decreases respiratory enzyme and Na(+)-K(+) ATPase activities, and leads to mitochondrial alterations in rat amygdala. Neurotox Res 29 (2016), 408–418.
23. [23] Das, U.N., Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression dementia, and Alzheimer's disease – but how and why?. Prostaglandins Leukot Essent Fatty Acids 78 (2008), 11–19.
24. [24] Hu, H., Wang, C., Jin, Y., Meng, Q., Liu, Q., Liu, K., et al. Alpha-lipoic acid defends homocysteine-induced endoplasmic reticulum and oxidative stress in HAECs. Biomed Pharmacother 80 (2016), 63–72.
25. [25] Wang, G., Siow, Y.L., Karmin, O., Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 352:Pt 3 (2000), 817–826.
26. [26] Boldyrev, A., Bryushkova, E., Mashkina, A., Vladychenskaya, E., Why is homocysteine toxic for the nervous and immune systems?. Curr Aging Sci 6 (2013), 29–36.
27. [27] Skovierova, H., Mahmood, S., Blahovcova, E., Hatok, J., Lehotsky, J., Murin, R., Effect of homocysteine on survival of human glial cells. Physiol Res 64 (2015), 747–754.
28. [28] Kim, B.J., Seo, M., Huh, J.K., Kwon, C.H., Kim, J.T., Sung, K.C., et al. Associations of plasma homocysteine levels with arterial stiffness in prehypertensive individuals. Clin Exp Hypertens 33 (2011), 411–417.
29. [29] Kinoshita, M., Numata, S., Tajima, A., Shimodera, S., Imoto, I., Ohmori, T., Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. Epigenetics 8 (2013), 584–590.
30. [30] Kok, D.E., Dhonukshe-Rutten, R.A., Lute, C., Heil, S.G., Uitterlinden, A.G., van der Velde, N., et al. The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects. Clin Epigenetics, 7, 2015, 121.
31. [31] Pana, A., Homocysteine and neuropsychiatric disease. Psychiatr Ann 45 (2015), 463–468.
32. [32] Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35 (2011), 804–817.
33. [33] Sharma, A.N., Bauer, I.E., Sanches, M., Galvez, J.F., Zunta-Soares, G.B., Quevedo, J., et al. Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry 54 (2014), 289–298.
34. [34] Peng, H.Y., Man, C.F., Xu, J., Fan, Y., Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B 16 (2015), 78–86.
35. [35] Nazef, K., Khelil, M., Chelouti, H., Kacimi, G., Bendini, M., Tazir, M., et al. Hyperhomocysteinemia is a risk factor for Alzheimer's disease in an Algerian population. Arch Med Res 45 (2014), 247–250.
36. [36] Beydoun, M.A., Beydoun, H.A., Gamaldo, A.A., Teel, A., Zonderman, A.B., Wang, Y., Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health, 14, 2014, 643.
37. [37] Nabi, H., Bochud, M., Glaus, J., Lasserre, A.M., Waeber, G., Vollenweider, P., et al. Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology 38 (2013), 2309–2318.
38. [38] Reif, A., Pfuhlmann, B., Lesch, K.P., Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005), 1162–1168.
39. [39] Bjelland, I., Tell, G.S., Vollset, S.E., Refsum, H., Ueland, P.M., Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 60 (2003), 618–626.
40. [40] Gu, P., DeFina, L.F., Leonard, D., John, S., Weiner, M.F., Brown, E.S., Relationship between serum homocysteine levels and depressive symptoms: the Cooper Center Longitudinal Study. J Clin Psychiatry 73 (2012), 691–695.
41. [41] Delport, D., Schoeman, R., van der Merwe, N., van der Merwe, L., Fisher, L.R., Geiger, D., et al. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C>T genotyping in South African patients diagnosed with depression: test development for clinical application. Metab Brain Dis 29 (2014), 377–384.
42. [42] Bala, K.A., Dogan, M., Mutluer, T., Kaba, S., Aslan, O., Balahoroglu, R., et al. Plasma amino acid profile in autism spectrum disorder (ASD). Eur Rev Med Pharmacol Sci 20 (2016), 923–929.
43. [43] Nishi, A., Numata, S., Tajima, A., Kinoshita, M., Kikuchi, K., Shimodera, S., et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 40 (2014), 1154–1163.
44. [44] Dias, V.V., Brissos, S., Cardoso, C., Andreazza, A.C., Kapczinski, F., Serum homocysteine levels and cognitive functioning in euthymic bipolar patients. J Affect Disord 113 (2009), 285–290.
45. [45] Bortolato, B., Miskowiak, K.W., Kohler, C.A., Maes, M., Fernandes, B.S., Berk, M., et al. Cognitive remission: a novel objective for the treatment of major depression?. BMC Med, 14, 2016, 9.
46. [46] Vuksan-Cusa, B., Jakovljevic, M., Sagud, M., Mihaljevic Peles, A., Marcinko, D., Topic, R., et al. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 189 (2011), 21–25.
47. [47] Ghanizadeh, A., Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. Dis Markers 35 (2013), 281–286.
48. [48] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
49. [49] Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25 (2010), 603–605.
50. [50] Handbook for Systematic reviews of Interventions Version 5.1.0. Higgins JPT, Green S (Editors). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org. [updated March 2011].
51. [51] Sistrom, C.L., Mergo, P.J., A simple method for obtaining original data from published graphs and plots. AJR Am J Roentgenol 174 (2000), 1241–1244.
52. [52] Hamilton, M., A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960), 56–62.
53. [53] Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133 (1978), 429–435.
54. [54] Carvalho, A.F., Kohler, C.A., Brunoni, A.R., Miskowiak, K.W., Herrmann, N., Lanctot, K.L., et al. Bias in peripheral depression biomarkers. Psychother Psychosom 85 (2016), 81–90.
55. [55] Carvalho, A.F., Kohler, C.A., Fernandes, B.S., Quevedo, J., Miskowiak, K.W., Brunoni, A.R., et al. Bias in emerging biomarkers for bipolar disorder. Psychol Med 46 (2016), 2287–2297.
56. [56] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
57. [57] Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
58. [58] Cohen, J., Statistical power analysis for the behavioral sciences. 2nd ed., 1988, Lawrence Erlbaum Associates, Inc., NJ.
59. [59] Lau, J., Ioannidis, J.P., Schmid, C.H., Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997), 820–826.
60. [60] Vargas, H.O., Nunes, S.O., Barbosa, D.S., Vargas, M.M., Cestari, A., Dodd, S., et al. Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sci 102 (2014), 65–71.
61. [61] Dittmann, S., Seemuller, F., Schwarz, M.J., Kleindienst, N., Stampfer, R., Zach, J., et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord 9 (2007), 63–70.
62. [62] Levine, J., Sela, B.A., Osher, Y., Belmaker, R.H., High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005), 1181–1191.
63. [63] Bell, I.R., Morrow, F.D., Read, M., Berkes, S., Perrone, G., Low thyroxine levels in female psychiatric inpatients with riboflavin deficiency: implications for folate-dependent methylation. Acta Psychiatr Scand 85 (1992), 360–363.
64. [64] Carney, M.W., Chary, T.K., Laundy, M., Bottiglieri, T., Chanarin, I., Reynolds, E.H., et al. Red cell folate concentrations in psychiatric patients. J Affect Disord 19 (1990), 207–213.
65. [65] Carney, M.W., Sheffield, B.F., Serum folic acid and B12 in 272 psychiatric in-patients. Psychol Med 8 (1978), 139–144.
66. [66] Coppen, A., Abou-Saleh, M.T., Plasma folate and affective morbidity during long-term lithium therapy. Br J Psychiatry 141 (1982), 87–89.
67. [67] Davison, K.M., Kaplan, B.J., Vitamin and mineral intakes in adults with mood disorders: comparisons to nutrition standards and associations with sociodemographic and clinical variables. J Am Coll Nutr 30 (2011), 547–558.
68. [68] Ellingrod, V.L., Taylor, S.F., Dalack, G., Grove, T.B., Bly, M.J., Brook, R.D., et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 32 (2012), 261–265.
69. [69] Issac, T.G., Soundarya, S., Christopher, R., Chandra, S.R., Vitamin B12 deficiency: an important reversible co-morbidity in neuropsychiatric manifestations. Indian J Psychol Med 37 (2015), 26–29.
70. [70] Lee, S., Chow, C.C., Shek, C.C., Wing, Y.K., Chen, C.N., Folate concentration in Chinese psychiatric outpatients on long-term lithium treatment. J Affect Disord 24 (1992), 265–270.
71. [71] Lundin, N.B., Niciu, M.J., Luckenbaugh, D.A., Ionescu, D.F., Richards, E.M., Vande Voort, J.L., et al. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry 47 (2014), 141–144.
72. [72] McKeon, P., Shelley, R., O'Regan, S., O'Broin, J., Serum and red cell folate and affective morbidity in lithium prophylaxis. Acta Psychiatr Scand 83 (1991), 199–201.
73. [73] McLaughlin, B., McMahon, A., Folate and depression. Br J Psychiatry, 162, 1993, 572.
74. [74] Permoda-Osip, A., Dorszewska, J., Bartkowska-Sniatkowska, A., Chlopocka-Wozniak, M., Rybakowski, J.K., Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 46 (2013), 227–228.
75. [75] Permoda-Osip, A., Dorszewska, J., Skibinska, M., Chlopocka-Wozniak, M., Rybakowski, J.K., Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates. Neuropsychobiology 68 (2013), 193–196.
76. [76] Silver, H., Vitamin B12 levels are low in hospitalized psychiatric patients. Isr J Psychiatry Relat Sci 37 (2000), 41–45.
77. [77] Snaith, R.P., Mehta, S., Raby, A.H., Serum folate and vitamin B12 in epileptics with and without mental illness. Br J Psychiatry 116 (1970), 179–183.
78. [78] Stern, S.L., Brandt, J.T., Hurley, R.S., Stagno, S.J., Stern, M.G., Smeltzer, D.J., Serum and red cell folate concentrations in outpatients receiving lithium carbonate. Int Clin Psychopharmacol 3 (1988), 49–52.
79. [79] Alexopoulos, P., Topalidis, S., Irmisch, G., Prehn, K., Jung, S.U., Poppe, K., et al. Homocysteine and cognitive function in geriatric depression. Neuropsychobiology 61 (2010), 97–104.
80. [80] Gultepe, M., Ozcan, O., Avsar, K., Cetin, M., Ozdemir, A.S., Gok, M., Urine methylmalonic acid measurements for the assessment of cobalamin deficiency related to neuropsychiatric disorders. Clin Biochem 36 (2003), 275–282.
81. [81] Henderson, J.G., Dawson, A.A., Serum vitamin-B12 levels in psychiatric patients on long-term psychotropic drug therapy. Br J Psychiatry 116 (1970), 439–442.
82. [82] Iosifescu, D.V., Papakostas, G.I., Lyoo, I.K., Lee, H.K., Renshaw, P.F., Alpert, J.E., et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiatry Res 140 (2005), 291–299.
83. [83] Ipcioglu, O.M., Ozcan, O., Gultepe, M., Ates, A., Basoglu, C., Cakir, E., Reduced urinary excretion of homocysteine could be the reason of elevated plasma homocysteine in patients with psychiatric illnesses. Clin Biochem 41 (2008), 831–835.
84. [84] Kaner, G., Soylu, M., Yuksel, N., Inanc, N., Ongan, D., Basmisirli, E., Evaluation of nutritional status of patients with depression. Biomed Res Int, 2015, 2015, 521481.
85. [85] Lok, A., Mocking, R.J., Assies, J., Koeter, M.W., Bockting, C.L., de Vries, G.J., et al. The one-carbon-cycle and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in recurrent major depressive disorder; influence of antidepressant use and depressive state?. J Affect Disord 166 (2014), 115–123.
86. [86] Mischoulon, D., Lamon-Fava, S., Selhub, J., Katz, J., Papakostas, G.I., Iosifescu, D.V., et al. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr 17 (2012), 76–86.
87. [87] Narayan, S.K., Verman, A., Kattimani, S., Ananthanarayanan, P.H., Adithan, C., Plasma homocysteine levels in depression and schizophrenia in South Indian Tamilian population. Indian J Psychiatry 56 (2014), 46–53.
88. [88] Scott, T.M., Tucker, K.L., Bhadelia, A., Benjamin, B., Patz, S., Bhadelia, R., et al. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry 12 (2004), 631–638.
89. [89] Wolfersdorf, M., Maier, V., Froscher, W., Laage, M., Straub, R., [Folic acid deficiency in patients hospitalized with depression? A pilot study of clinical relevance]. Nervenarzt 64 (1993), 269–272.
90. [90] Hasanah, C.I., Khan, U.A., Musalmah, M., Razali, S.M., Reduced red-cell folate in mania. J Affect Disord 46 (1997), 95–99.
91. [91] Chen, Z., Liu, Y., Zhang, D., Liu, Z., Wang, P., Zhou, D., et al. C677T methylenetetrahydrofolate reductase gene polymorphisms in bipolar disorder: an association study in the Chinese population and a meta-analysis of genetic association studies. Neurosci Lett 449 (2009), 48–51.
92. [92] Jonsson, E.G., Larsson, K., Vares, M., Hansen, T., Wang, A.G., Djurovic, S., et al. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. Am J Med Genet B Neuropsychiatr Genet 147B (2008), 976–982.
93. [93] Kempisty, B., Bober, A., Luczak, M., Czerski, P., Szczepankiewicz, A., Hauser, J., et al. Distribution of 1298A>C polymorphism of methylenetetrahydrofolate reductase gene in patients with bipolar disorder and schizophrenia. Eur Psychiatry 22 (2007), 39–43.
94. [94] Kempisty, B., Mostowska, A., Gorska, I., Luczak, M., Czerski, P., Szczepankiewicz, A., et al. Association of 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. Neurosci Lett 400 (2006), 267–271.
95. [95] Kempisty, B., Sikora, J., Lianeri, M., Szczepankiewicz, A., Czerski, P., Hauser, J., et al. MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet 17 (2007), 177–181.
96. [96] Malhotra, N., Kulhara, P., Chakrabarti, S., Grover, S., A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord 150 (2013), 653–658.
97. [97] Arinami, T., Yamada, N., Yamakawa-Kobayashi, K., Hamaguchi, H., Toru, M., Methylenetetrahydrofolate reductase variant schizophrenia/depression. Am J Med Genet 74 (1997), 526–528.
98. [98] Davison, K.M., Kaplan, B.J., Nutrient intakes are correlated with overall psychiatric functioning in adults with mood disorders. Can J Psychiatry 57 (2012), 85–92.
99. [99] Hickie, I., Scott, E., Naismith, S., Ward, P.B., Turner, K., Parker, G., et al. Late-onset depression: genetic, vascular and clinical contributions. Psychol Med 31 (2001), 1403–1412.
100. [100] Kunugi, H., Fukuda, R., Hattori, M., Kato, T., Tatsumi, M., Sakai, T., et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psychiatry 3 (1998), 435–437.
101. [101] Tan, E.C., Chong, S.A., Lim, L.C., Chan, A.O., Teo, Y.Y., Tan, C.H., et al. Genetic analysis of the thermolabile methylenetetrahydrofolate reductase variant in schizophrenia and mood disorders. Psychiatr Genet 14 (2004), 227–231.
102. [102] Callaghan, N., Mitchell, R., Cotter, P., The relationship of serum folic acid and vitamin B 12 levels to psychosis in epilepsy. Ir J Med Sci 8 (1969), 497–505.
103. [103] Coppen, A., Swade, C., Jones, S.A., Armstrong, R.A., Blair, J.A., Leeming, R.J., Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 16 (1989), 103–107.
104. [104] Ezzaher, A., Mouhamed, D.H., Mechri, A., Omezzine, A., Neffati, F., Douki, W., et al. Hyperhomocysteinemia in Tunisian bipolar I patients. Psychiatry Clin Neurosci 65 (2011), 664–671.
105. [105] Ozbek, Z., Kucukali, C.I., Ozkok, E., Orhan, N., Aydin, M., Kilic, G., et al. Effect of the methylenetetrahydrofolate reductase gene polymorphisms on homocysteine, folate and vitamin B12 in patients with bipolar disorder and relatives. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008), 1331–1337.
106. [106] Chiarani, F., Tramontina, J.F., Cereser, K.M., Kunz, M., Paim, L., Vargas, C.R., et al. Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder. Rev Bras Psiquiatr 35 (2013), 157–160.
107. [107] Bromberg, A., Bersudsky, Y., Levine, J., Agam, G., Global leukocyte DNA methylation is not altered in euthymic bipolar patients. J Affect Disord 118 (2009), 234–239.
108. [108] Vuksan-Cusa, B., Sagud, M., Jakovljevic, M., Peles, A.M., Jaksic, N., Mihaljevic, S., et al. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry 67 (2013), 320–325.
109. [109] Osher, Y., Bersudsky, Y., Silver, H., Sela, B.A., Belmaker, R.H., Neuropsychological correlates of homocysteine levels in euthymic bipolar patients. J Affect Disord 105 (2008), 229–233.
110. [110] Osher, Y., Sela, B.A., Levine, J., Belmaker, R.H., Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. Bipolar Disord 6 (2004), 82–86.
111. [111] Doganavsargil Baysal, G.O., Gokmen, Z., Akbas, H., Cinemre, B., Metin, O., Karaman, T., [Association of serum homocysteine and methionine levels with cognition and functioning in bipolar disorder]. Turk Psikiyatri Derg 24 (2013), 7–16.
112. [112] Dittmann, S., Seemuller, F., Grunze, H.C., Schwarz, M.J., Zach, J., Fast, K., et al. The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. J Clin Psychiatry 69 (2008), 899–906.
113. [113] Puig-Alcaraz, C., Fuentes-Albero, M., Calderon, J., Garrote, D., Cauli, O., Increased homocysteine levels correlate with the communication deficit in children with autism spectrum disorder. Psychiatry Res 229 (2015), 1031–1037.
114. [114] Ganguly, P., Alam, S.F., Role of homocysteine in the development of cardiovascular disease. Nutr J, 14, 2015, 6.
115. [115] Jadavji, N.M., Wieske, F., Dirnagl, U., Winter, C., Methylenetetrahydrofolate reductase deficiency alters levels of glutamate and gamma-aminobutyric acid in brain tissue. Mol Genet Metab Rep 3 (2015), 1–4.
116. [116] Yang, Z., Wang, L., Zhang, W., Wang, X., Zhou, S., Plasma homocysteine involved in methylation and expression of thrombomodulin in cerebral infarction. Biochem Biophys Res Commun 473 (2016), 1218–1222.
117. [117] Fernandes, B.S., Dash, S., Jacka, F., Dodd, S., Carvalho, A.F., Kohler, C.A., et al. Leptin in bipolar disorder: a systematic review and meta-analysis. Eur Psychiatry 35 (2016), 1–7.
118. [118] Ludwig, B., Dwivedi, Y., Dissecting bipolar disorder complexity through epigenomic approach. Mol Psychiatry 21 (2016), 1490–1498.
119. [119] Mitchell, E.S., Conus, N., Kaput, J., B vitamin polymorphisms and behavior: evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. Neurosci Biobehav Rev 47 (2014), 307–320.
120. [120] Durga, J., van Boxtel, M.P., Schouten, E.G., Bots, M.L., Kok, F.J., Verhoef, P., Folate and the methylenetetrahydrofolate reductase 677C->T mutation correlate with cognitive performance. Neurobiol Aging 27 (2006), 334–343.
121. [121] Schiepers, O.J., van Boxtel, M.P., de Groot, R.H., Jolles, J., Bekers, O., Kok, F.J., et al. Genetic variation in folate metabolism is not associated with cognitive functioning or mood in healthy adults. Prog Neuropsychopharmacol Biol Psychiatry 35 (2011), 1682–1688.
122. [122] Yeh, T.K., Hu, C.Y., Yeh, T.C., Lin, P.J., Wu, C.H., Lee, P.L., et al. Association of polymorphisms in BDNF, MTHFR, and genes involved in the dopaminergic pathway with memory in a healthy Chinese population. Brain Cogn 80 (2012), 282–289.
123. [123] Eszlari, N., Kovacs, D., Petschner, P., Pap, D., Gonda, X., Elliott, R., et al. Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression. Transl Psychiatry, 6, 2016, e745.
124. [124] Pirchl, M., Ullrich, C., Humpel, C., Differential effects of short- and long-term hyperhomocysteinaemia on cholinergic neurons, spatial memory and microbleedings in vivo in rats. Eur J Neurosci 32 (2010), 1516–1527.
125. [125] Martinez-Aran, A., Vieta, E., Cognition as a target in schizophrenia, bipolar disorder and depression. Eur Neuropsychopharmacol 25 (2015), 151–157.
126. [126] Miskowiak, K.W., Carvalho, A.F., Vieta, E., Kessing, L.V., Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. Eur Neuropsychopharmacol 26 (2016), 1541–1561.
127. [127] Vieta, E., Torrent, C., Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry 15 (2016), 288–289.
128. [128] Sharpley, A.L., Hockney, R., McPeake, L., Geddes, J.R., Cowen, P.J., Folic acid supplementation for prevention of mood disorders in young people at familial risk: a randomised, double blind, placebo controlled trial. J Affect Disord 167 (2014), 306–311.
129. [129] Bedson, E., Bell, D., Carr, D., Carter, B., Hughes, D., Jorgensen, A., et al. Folate Augmentation of Treatment – Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technol Assess 18 (2014), vii–viii [1–159].
130. [130] Almeida, O.P., Ford, A.H., Flicker, L., Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int Psychogeriatr 27 (2015), 727–737.
131. [131] Wu, D., Pardridge, W.M., Blood-brain barrier transport of reduced folic acid. Pharm Res 16 (1999), 415–419.
132. [132] Pietrzik, K., Bailey, L., Shane, B., Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 49 (2010), 535–548.
133. [133] Geddes, J.R., Gardiner, A., Rendell, J., Voysey, M., Tunbridge, E., Hinds, C., et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3 (2016), 31–39.
134. [134] Dankner, R., Chetrit, A., Dror, G.K., Sela, B.A., Physical activity is inversely associated with total homocysteine levels, independent of C677T MTHFR genotype and plasma B vitamins. Age 29 (2007), 219–227.
135. [135] Vancampfort, D., Firth, J., Schuch, F., Rosenbaum, S., De Hert, M., Mugisha, J., et al. Physical activity and sedentary behavior in people with bipolar disorder: a systematic review and meta-analysis. J Affect Disord 201 (2016), 145–152.
136. [136] Deminice, R., Ribeiro, D.F., Frajacomo, F.T.T., The effects of acute exercise and exercise training on plasma homocysteine: a meta-analysis. PLoS ONE, 11(3), 2016, e0151653, 10.1371/journal.pone.0151653.
137. [137] Vancampfort, D., Stubbs, B., Physical activity and metabolic disease among people with affective disorders: prevention, management and implementation. J Affect Disord 201 (2016), 145–152.
138. [138] Maron, B.A., Loscalzo, J., The treatment of hyperhomocysteinemia. Annu Rev Med 60 (2009), 39–54.
139. [139] Misiak, B., Frydecka, D., Slezak, R., Piotrowski, P., Kiejna, A., Elevated homocysteine level in first-episode schizophrenia patients – the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab Brain Dis 29 (2014), 661–670.
140. [140] Gaikwad, N.W., Mass spectrometry evidence for formation of estrogen-homocysteine conjugates: estrogens can regulate homocysteine levels. Free Radic Biol Med 65 (2013), 1447–1454.
141. [141] Slyepchenko, A., Maes, M., Jacka, F.N., Kohler, C.A., Barichello, T., McIntyre, R.S., et al. Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. Psychother Psychosom 86 (2016), 31–46.
142. [142] LeBlanc, J.G., Laino, J.E., del Valle, M.J., Vannini, V., van Sinderen, D., Taranto, M.P., et al. B-group vitamin production by lactic acid bacteria – current knowledge and potential applications. J Appl Microbiol 111 (2011), 1297–1309.
143. [143] Rogers, G.B., Keating, D.J., Young, R.L., Wong, M.L., Licinio, J., Wesselingh, S., From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry 21 (2016), 738–748.
144. [144] Dinan, T.G., Cryan, J.F., Melancholic microbes: a link between gut microbiota and depression?. Neurogastroenterol Motil 25 (2013), 713–719.
145. [145] Selhub, J., Homocysteine metabolism. Annu Rev Nutr 19 (1999), 217–246.
146. [146] Obeid, R., Herrmann, W., Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 580 (2006), 2994–3000.
147. [147] Young, J.J., Silber, T., Bruno, D., Galatzer-Levy, I.R., Pomara, N., Marmar, C.R., Is there progress? An overview of selecting biomarker candidates for major depressive disorder. Front Psychiatry, 7, 2016, 72.
148. [148] Fernandes, B.S., Gama, C.S., Kauer-Sant'Anna, M., Lobato, M.I., Belmonte-de-Abreu, P., Kapczinski, F., Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 43 (2009), 1200–1204.